바이오시밀러 모노클로널 항체 시장 : 항체 클래스, 분자 클래스, 제형, 치료 유형, 치료 영역, 최종사용자별 - 세계 예측(2026-2032년)

The Biosimilar Monoclonal Antibodies Market is projected to grow by USD 19.05 billion at a CAGR of 11.49% by 2032.

Biosimilar Monoclonal Antibodies Market Executive Summary

Biosimilar monoclonal antibodies are moving from a cost-containment option to a core pillar of biologic therapy access across oncology, immunology, ophthalmology, and inflammatory diseases. These products are approved through rigorous comparability pathways requiring analytical, nonclinical, pharmacokinetic, immunogenicity, and clinical evidence showing no clinically meaningful differences from reference biologics in safety, purity, and potency.

The market is shaped by patent expirations for high-revenue biologics, increasing payer pressure, and expanding physician confidence as real-world evidence accumulates. Regulatory precedents from the FDA, EMA, WHO, and national agencies have strengthened trust in biosimilar monoclonal antibodies, while hospital formularies and specialty pharmacy channels are accelerating adoption where procurement systems reward value-based competition.

Transformative Shifts Reshaping Biosimilar Monoclonal Antibodies

The competitive landscape is undergoing a structural shift as biosimilar monoclonal antibodies expand beyond early infliximab, trastuzumab, rituximab, and bevacizumab categories into broader immunology and ophthalmology opportunities. The U.S. entry of multiple adalimumab biosimilars in 2023 marked a pivotal access milestone, reinforcing that payer contracting, interchangeability decisions, formulary placement, and channel strategy can be as important as regulatory approval.

Manufacturers are responding with more efficient cell-line development, advanced analytics, high-concentration formulations, citrate-free presentations, and device differentiation. At the same time, health systems are tightening evidence expectations around switching, extrapolation of indications, immunogenicity, pharmacovigilance, and supply reliability, making manufacturing quality and post-market data central competitive differentiators.

Cumulative Impact of Artificial Intelligence on Biosimilar Development

Artificial intelligence is cumulatively improving the biosimilar monoclonal antibody value chain by accelerating candidate characterization, predicting critical quality attributes, optimizing cell-culture parameters, and supporting comparability assessments. Machine learning models are increasingly used to interpret high-dimensional analytical data from glycosylation, charge variants, aggregation, binding affinity, and potency assays, helping teams identify variability earlier in development.

AI also supports regulatory intelligence, pharmacovigilance signal detection, literature surveillance, demand planning, and market access strategy. However, adoption remains bounded by validation, data integrity, model explainability, cybersecurity, and regulatory documentation requirements. The most credible near-term impact is not replacing biosimilar evidence generation, but reducing development risk, improving manufacturing consistency, and strengthening post-launch monitoring.

Key Regional Insights Across Global Biosimilar Monoclonal Antibody Markets

Asia-Pacific is emerging as a strategic biosimilar monoclonal antibodies hub, supported by biologics manufacturing capacity in China, India, South Korea, and Japan, along with rising demand for affordable oncology, autoimmune, and ophthalmology therapies. Regulatory reforms across the region, including biosimilar guidelines aligned with international comparability principles, are improving confidence while local production policies help address affordability and supply continuity.

North America remains highly influenced by payer contracting, FDA biosimilar and interchangeable designations, reimbursement design, and specialty pharmacy dynamics, with the United States driving commercial complexity and Canada emphasizing provincial switching policies. Latin America is advancing through procurement-led access models, reliance pathways, and regulatory convergence, with Brazil and Mexico playing important roles in public health purchasing and biosimilar policy development.

Europe remains the most mature adoption environment, supported by EMA experience, national tendering systems, physician familiarity with biosimilar switching, and extensive real-world evidence in immunology and oncology. The Middle East, especially GCC markets, is expanding biologics access through public-sector investment, hospital modernization, and national health transformation programs, while Africa shows long-term potential where cold-chain infrastructure, pricing, local regulatory capacity, and procurement financing continue to shape uptake.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO Markets

ASEAN markets are prioritizing affordability, regulatory capacity building, and local manufacturing partnerships as demand rises for oncology and immunology biologics. Countries in the region are increasingly using national reimbursement lists, hospital tenders, and technology transfer collaborations to improve access while maintaining pharmacovigilance requirements for complex biologics.

The GCC is using centralized purchasing, hospital modernization, and national health transformation programs to expand biosimilar access, particularly in Saudi Arabia and the United Arab Emirates. The European Union remains the benchmark for biosimilar policy maturity, with centralized EMA evaluation, national substitution or switching frameworks, and country-level tendering driving competition and physician acceptance.

BRICS economies are strategically important because China, India, Brazil, and Russia combine large patient populations with domestic biologics ambitions, while South Africa's access priorities highlight the need for affordability and reliable supply. G7 markets offer strong regulatory predictability and reimbursement sophistication, and NATO members in Europe and North America are increasingly focused on medicine supply resilience, biologic affordability, and secure pharmaceutical manufacturing networks.

Key Country Insights in Major Biosimilar Monoclonal Antibody Markets

The United States is a major commercial opportunity shaped by FDA approvals, interchangeable biosimilar designations, reimbursement design, pharmacy benefit management, and provider-administered buy-and-bill economics. Canada continues to promote biosimilar use through provincial reimbursement and switching policies, while Mexico and Brazil use public procurement, regulatory modernization, and institutional purchasing to broaden biologic access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established biosimilar prescribing experience, although tendering, physician autonomy, substitution policy, and payer incentives vary by country. Russia has emphasized domestic biologics production and import substitution policies, while China and India combine large treatment-naive populations with expanding biosimilar manufacturing capacity, improving access to monoclonal antibody therapies across oncology and inflammatory diseases.

Japan maintains stringent regulatory standards and a cautious but evidence-based adoption environment, while South Korea is recognized as a major global biosimilar manufacturing base supported by advanced biologics infrastructure and regulatory experience. Australia supports uptake through reimbursement policy, reference pricing mechanisms, and clinician education, making it an important developed Asia-Pacific market for evidence-based biosimilar adoption.

Actionable Recommendations for Biosimilar Monoclonal Antibody Leaders

Industry leaders should prioritize portfolios aligned with high-value biologic patent expirations, clear differentiation in formulation or delivery, and strong supply reliability. Commercial success requires early payer engagement, robust health economic evidence, switching education, transparent immunogenicity communication, and pharmacovigilance programs that build confidence among prescribers, pharmacists, and patients.

Organizations should invest in advanced analytics, quality-by-design manufacturing, and real-world evidence platforms to demonstrate consistency beyond approval. Partnerships with hospitals, specialty pharmacies, government procurement agencies, and local manufacturers can improve market entry, particularly in price-sensitive regions where tender performance, cold-chain readiness, and access commitments determine scale.

Research Methodology for Evidence-Based Market Assessment

This executive summary is developed using a structured secondary research approach grounded in publicly available regulatory, clinical, policy, and market-access evidence. Core references include biosimilar guidance and approval databases from the FDA, EMA, WHO, national regulatory authorities, public procurement frameworks, peer-reviewed literature, clinical trial registries, pharmacovigilance resources, and recognized healthcare policy sources.

The methodology emphasizes triangulation across regulatory approvals, patent and exclusivity events, payer policy trends, therapeutic adoption patterns, switching guidance, and manufacturing capabilities. Insights were assessed for relevance to monoclonal antibody biosimilars, with preference for verifiable evidence over promotional claims and a focus on commercially actionable trends without relying on market sizing, market share, or forecasting assumptions.

Conclusion: Biosimilar Monoclonal Antibodies Enter a Scaled Access Era

Biosimilar monoclonal antibodies are becoming essential to sustainable biologic care as health systems seek to reduce costs while preserving clinical outcomes. The market is no longer defined only by approval counts; it is increasingly driven by interchangeability, contracting strategy, physician confidence, real-world evidence, pharmacovigilance, and manufacturing excellence.

Organizations that combine scientific rigor with agile market access execution will be best positioned to strengthen adoption. As AI-enabled analytics, regulatory maturity, and global procurement reforms advance, biosimilar monoclonal antibodies are expected to play a larger role in expanding patient access to high-value biologic therapies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biosimilar Monoclonal Antibodies Market, by Antibody Class

• 7.1. Chimeric Monoclonal Antibodies
• 7.2. Humanized Monoclonal Antibodies

8. Biosimilar Monoclonal Antibodies Market, by Molecule Class

• 8.1. Adalimumab
• 8.2. Infliximab
• 8.3. Rituximab
• 8.4. Trastuzumab
• 8.5. Bevacizumab
• 8.6. Ranibizumab

9. Biosimilar Monoclonal Antibodies Market, by Dosage Form

• 9.1. Liquid Solution
• 9.2. Lyophilized Powder
• 9.3. Prefilled Syringe

10. Biosimilar Monoclonal Antibodies Market, by Treatment Type

• 10.1. Monotherapy
• 10.2. Combination Therapy

11. Biosimilar Monoclonal Antibodies Market, by Therapeutic Area

• 11.1. Immunology
• 11.2. Oncology
• 11.3. Ophthalmology
• 11.4. Rheumatology
• 11.5. Autoimmune & Inflammatory Diseases

12. Biosimilar Monoclonal Antibodies Market, by End User

• 12.1. Specialty Clinics
• 12.2. Hospitals
• 12.3. Home Healthcare

13. Biosimilar Monoclonal Antibodies Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Biosimilar Monoclonal Antibodies Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Biosimilar Monoclonal Antibodies Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Alvotech hf
• 17.2. Amgen Inc.
• 17.3. Aurobindo Pharma Ltd.
• 17.4. Bio-Thera Solutions, Ltd.
• 17.5. Biocon Ltd.
• 17.6. Boehringer Ingelheim International GmbH
• 17.7. Celltrion, Inc.
• 17.8. Coherus BioSciences, Inc.
• 17.9. Dr. Reddy's Laboratories Ltd.
• 17.10. Formycon AG
• 17.11. Fresenius Kabi AG
• 17.12. Intas Pharmaceuticals Ltd.
• 17.13. Lupin Ltd.
• 17.14. Mabwell Bioscience
• 17.15. Merck KGaA
• 17.16. Pfizer Inc.
• 17.17. Polpharma Biologics Group
• 17.18. Qilu Pharmaceutical Co., Ltd.
• 17.19. Reliance Life Sciences
• 17.20. Samsung Bioepis Co., Ltd.
• 17.21. Sandoz International GmbH
• 17.22. Shanghai Henlius Biotech, Inc.
• 17.23. Stada Arzneimittel AG